Showing results (2081-2090 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|April 28, 2005
Pharmacoeconomic analyses using discrete event simulationJ Jaime Caro
Pharmacoeconomics|April 28, 2005
Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitisMark A Miller, Cathryn K Shahab
Pharmacoeconomics|May 7, 2005
The value of clopidogrel in addition to standard therapy in reducing atherothrombotic eventsWilliam Weintraub, Bengt Jönsson, Michel Bertrand
Pharmacoeconomics|November 5, 2004
Use and cost of antiretrovirals in France 1995-2000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) databaseYves A Flori, Marc le Vaillant
Pharmacoeconomics|December 23, 2004
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE studyFredrik Borgström, Olof Johnell, John A Kanis, et al.
Pharmacoeconomics|February 8, 2006
Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic studyDavid Salkever, Eric Slade, Mustafa Karakus
Pharmacoeconomics|February 8, 2006
Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the NetherlandsJasper M Bos, Hans C Rümke, Robert Welte, et al.
Pharmacoeconomics|December 20, 2007
Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategiesAndrea M Anonychuk, Andrea C Tricco, Chris T Bauch, et al.
Pharmacoeconomics|March 29, 2008
Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO studyMartin Knapp, Frank Windmeijer, Jacqueline Brown, et al.
Pharmacoeconomics|March 8, 2006
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspectiveJonathan Karnon, Thomas Delea, Stephen R D Johnston, et al.
Pageof 336